메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

'김갑성' 기자의 전체기사

Korea Innovation Foundation selects 2 Innovative bio heal…

DAEJEON, South Korea, Nov. 26, 2025 -- Korea Innovation Foundation (INNOPOLIS), currently operating the 2025 Global Technology Commercialization Support Program (North America), announces that 2 innovative companies, LEEBIO, and Airlab are chosen for the support program. This initiative selects innovative technology companies in the fields of machinery, energy, AI/IoT and bio health. The program provides comprehensive consulting support to help these companies apply their technologies and products on a trial basis to local facilities or projects operated by overseas companies and insti
- 김갑성 기자
- 2025-11-26 13:45
Chiron Medical Advances Women's Health with Expanded "1:…

[ 메디채널 김갑성 기자 ] 300 Free 3D Mammogram Screenings Donated to Community Women, Championing Self-Care and Compassionate Support HONG KONG, Nov. 26, 2025 -- Building on its commitment to accessible healthcare, Chiron Medical Group (Referred as "Chiron") launched the "1:1 Breast Health Empowerment Charity Campaign" earlier this year, delivering 105 free 3D mammogram screenings and personalized medical consultations to underprivileged women. Through a series of six interactive breast health workshops, the initiative successfully engaged numerous low-income participants,
- 김갑성 기자
- 2025-11-26 13:03
The Unseen Itch: Over Half of Singaporeans With Eczema Str…

[ 메디채널 김갑성 기자 ] A recently concluded survey by Medical Channel Asia sheds light on the debilitating effects of constant itch caused by eczema. SINGAPORE, Nov. 25, 2025 -- A new ground-up survey "The Unseen Itch: How Eczema Disrupts Daily Life in Singapore" by Medical Channel Asia has uncovered a stark and often overlooked reality about itch. For people living with atopic dermatitis, or eczema, itch is not a minor inconvenience – it is a daily, debilitating force that silently dictates how they sleep, work, socialise, and even how they see themselves. The init
- 김갑성 기자
- 2025-11-26 10:33
Precious Hospital Sdn. Bhd. to Launch Cancer Centre and H…

[ 메디채널 김갑성 기자 ] First cyclotron outside Klang Valley to anchor Malaysia's advanced cancer care ecosystem KEY-HIGHLIGTHS RM500 million investment in advanced cancer care infrastructure State-of-the-art diagnostic and treatment facilities, including a nuclear medicine centre First cyclotron outside the Klang Valley enabling local radioisotope production for cancer detection and therapy Located in Larkin Sentral within the Johor–Singapore Special Economic Zone (JS-SEZ) Phase One projected to create around 1,000 direct and indirect jobs JOHOR BAHRU, Malaysia and
- 김갑성 기자
- 2025-11-26 10:00
Prestige Biopharma and Biosidus Enter Exclusive License A…

SINGAPORE, Nov. 26, 2025 -- Prestige Biopharma, a biopharmaceutical company specializing in antibody therapeutics, today announced an exclusive license and supply agreement with Biosidus, a biotechnology company headquartered in Buenos Aires, Argentina, with decades of experience in biosimilar development and commercialization, for the commercialization of Tuznue® (trastuzumab) across Latin American markets, including Argentina, Mexico, Bolivia, and Paraguay. Tuznue® is a biosimilar to Herceptin® (trastuzumab), approved for the treatment of breast cancer and metastatic gast
- 김갑성 기자
- 2025-11-26 09:06
Professor Chan Heum Park's Team at Hallym University Chunch…

SEOUL, South Korea, Nov. 26, 2025 -- Chan Hum Park, M.D., Ph.D., Professor of Otolaryngology at Hallym University Chuncheon Sacred Heart Hospital and Director of the Nano-Bio Regenerative Medical Institute at Hallym University, leads the research team whose space biology payload, BioCabinet, will launch aboard the Nuri rocket's fourth flight on November 27, as part of the mission carrying the Next-Generation Medium Satellite-3. BioCabinet is a research platform with a bio 3D printer and stem cell differentiation incubator. Designed to fabricate artificial heart tissue and evalu
- 김갑성 기자
- 2025-11-26 07:30
알츠하이머 협회, 경구용 세마글루티드 3상 임상시험 결과에 대한 입장 발표

- 이번 임상시험 결과는 다양한 신약 후보 물질에 대한 꾸준한 연구의 필요성을 시사한다 시카고, 2025년 11월 26일 -- 알츠하이머 협회(Alzheimer's Association)가 알츠하이머병 진행 속도를 유의미하게 늦추지 못했다는 evoke 및 evoke+ 임상시험 결과에 아쉬움을 표했다. 해당 연구에서는 초기 알츠하이머병 환자를 대상으로 경구용 세마글루티드 약의 효능을 시험했다. 조안 파이크(Joanne Pike, DrPH) 알츠하이머 협회장은 "비록 바라던 결과는 아니지만, 이번 임상시험 데이터가 알츠하이머병이라는 치명적인 질병을 이해하는 데 도움이 될 것"이라면서 "임상시험 결과와 무관하게, 이번 임상시험 데이터는 알츠하이머병에 대한 이해도를 높이고, 향후 임상 연구의 방향성을 정하는 데 일조할 것이다. 의학계의 연구 환경이 꾸준히 다각화 및 확장되고 있으므로 알츠하이머병 치료와 예방도 여전히 낙관적"이라고 전망했다. 임상시험을 진행했던 제약 회사 노보 노디스크(Novo Nordisk)는 "두 임상시험에서 공통적으로 세마글루티드 치료 후 바이오마
- 김갑성 기자
- 2025-11-26 00:33
Innova Therapeutics to Advance Novel Cancer Treatment w…

The acquisition of Enci Therapeutics will advance Innova Therapeutics' lead program, IVT-8086, a humanized monoclonal antibody targeting SFRP2 which is expressed in most solid and hematological cancers. IVT-8086 is the only cancer therapeutic that targets multiple cell types associated with cancer including the tumor, and multiple components of the tumor microenvironment including endothelial cells, T-cells, and tumor associated macrophages (TAMs) through a common pathway. MT PLEASANT, S.C., Nov. 25, 2025 -- Innova Therapeutics, a biopharmaceutical company, has announced
- 김갑성 기자
- 2025-11-25 23:06
BON Announced Next-Gen of Tea Pigment Digestive Health Pro…

XI'AN, China, Nov. 25, 2025 -- Bon Natural Life Limited (Nasdaq: BON) ("BON" or the "Company"), a leading bio-ingredient solution provider in the natural, health and personal care industry, today announced a non-exclusive cooperation agreement with Beijing Huahai Keyuan Technology Co. Ltd. ("Huahai Keyuan") a prominent health products distributor in China. The term of the agreement is 36 months with a total contract value of US$26 million. Pursuant to the agreement, Huahai Keyuan will sell and distribute BON's second-generation tea pigment-based digestive health
- 김갑성 기자
- 2025-11-25 22:41
Neurophet and The Florey Strengthen Research Collabora…

Aiming to evaluate the utility of blood-based and other biomarkers for Alzheimer's disease diagnosis and management Joint research to enhance dementia diagnosis using the brain neurodegeneration imaging software 'Neurophet AQUA' SEOUL, South Korea, Nov. 25, 2025 -- Neurophet (Co-CEOs Jake Junkil Been and Donghyeon Kim), an artificial intelligence (AI) solution company for brain disorders diagnosis and treatment, announced on 25th that it will collaborate with the Florey Institute of Neuroscience and Mental Health (The Florey) in Australia on joint research using its brai
- 김갑성 기자
- 2025-11-25 22:00

이전

1 2 3 4 5 6 7 8 9 10

많이 본 기사

최근기사

2025-11-26_WED

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 11월 26일 15시 20분